Ranbaxy’s CEO stepping down and appointments at Avid, the USP and Novavax – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Medicine Corporate governance

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Ranbaxy’s CEO stepping down and appointments at Avid, the USP and Novavax.

Atul Sobti ​has stepped down as CEO and managing director of Ranbaxy Laboratories​. Sobti joined Ranbaxy in 2007 and was made CEO in May 2009. Arun Sawhney​, the president of Ranbaxy’s global pharma business, is replacing Sobti as managing director.

Avid Radiopharmaceuticals ​has named Mark Mintun ​as chief medical officer. Before filling the newly created position Mintun worked at the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St Louis, Missouri, US.

Amy Karren​, director of scientific development at Nelson Laboratories​, has been elected to serve a five-year term on the US Pharmacopeia Convention ​(USP​) small molecules monographs 1 committee.

The International AIDS Vaccine Initiative​ (IAVI​) has appointed Michael Caulfield ​as executive director of its vaccine design and development laboratory. Caulfield spent the past 16 years at Merck & Co and before that worked as a researcher at the Cleveland Clinic.

Richard Douglas ​has been elected to the board of directors at Novavax​. Douglas is currently SVP, corporate development at Genzyme and previously worked at Integrated Genetics.

KV Pharmaceutical ​has named Robert Baldini ​as an independent member of its board of directors. Baldini has worked in the pharma industry for 50 years at companies including Pfizer, Geigy, Key Pharmaceuticals and Kos Pharmaceuticals.

Craig Eagle ​has joined the scientific advisory board at Generex Biotechnology​. Eagle is the current VP of strategic alliances and partnerships at Pfizer’s oncology unit.

Oxis International ​has appointed John Repine ​to its scientific advisory board. Repine is the director of the Webb-Waring Center for Oxidative Stress Research at the University of Denver Colorado Health Sciences Center.

Ian Weatherhead ​has been named as director of communications for Sanofi-Aventis UK​. Weatherhead joins from UCB and earlier in his career worked at AstraZeneca and Syngenta.

Pinnacle Biologics ​has elected James Foght ​to its board of directors. Foght was a co-founder of DuPont Pharmaceuticals, founder of Vector Securities International and holds a number of advisory positions.

Related topics Markets & Regulations

Related news

Show more

Follow us


View more